Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Civitas Therapeutics
Chelsea, Massachusetts, United Statescivitastherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Civitas Therapeutics demonstrated positive Phase 2 and Phase 2b results with CVT-301 (inhaled levodopa) showing rapid and durable improvement for "OFF" episodes in Parkinson’s disease; safety and tolerability were favorable compared to oral standards and pivotal Phase 3 was planned prior to acquisition[4][13].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Partnerships
The Michael J. Fox Foundation for Parkinson’s Research (clinical funding support)
Beyond the preview
Go deeper on Civitas Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Civitas Therapeutics.